DrugPatentWatch Database Preview

Litigation Details for JANSSEN PRODUCTS, L.P. v. LUPIN LIMITED (D.N.J. 2010)

« Back to Dashboard

JANSSEN PRODUCTS, L.P. v. LUPIN LIMITED (D.N.J. 2010)

Docket		Date Filed	2010-11-15
Court	District Court, D. New Jersey	Date Terminated	2014-08-19
Cause	35:271 Patent Infringement	Assigned To	William H. Walls
Jury Demand	Defendant	Referred To	Cathy L. Waldor
Parties	CIPLA LTD.; G.D. SEARLE; G.D. SEARLE, LLC; JANSSEN PRODUCTS, L.P.; JANSSEN R&D IRELAND; JANSSEN R&D IRELAND; JANSSEN SCIENCES IRELAND UC; LUPIN LIMITED; LUPIN PHARMACEUTICALS INC.; MYLAN INC.; MYLAN PHARMACEUTICALS INC.; PHV THEODORE J. CHIACCHIO; TEVA PHARMACEUTICAL INDUSTRIES, LTD.; TEVA PHARMACEUTICALS USA, INC.; THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS; TIBOTEC INC.; TIBOTEC PHARMACEUTICALS; UNITED STATES OF AMERICA
Patents	5,843,946; 6,248,775; 7,470,506; 7,700,645; RE42,889; RE43,596
Attorneys	ANJAN MISHRA; CARISSA L. RODRIGUE; CHARLES MICHAEL LIZZA; COREY R. ANTHONY; DANIEL J. GIBBONS; ELINA SLAVIN; G.D. Searle; JAMES E. CECCHI; JOHN EDMUND FLAHERTY; JOHN G. NEW; JONATHAN M.H. SHORT; JOSEPH B. CRYSTAL; KIRBY WING-KAY LEE; MARK H. ANANIA; MAYRA VELEZ TARANTINO; MELISSA E. FLAX; MICHAEL CROSS; MICHAEL E. PATUNAS; RAVIN R. PATEL; SARAH ANN SULLIVAN; SYMONE J. REDWINE; WALTER WAYNE BROWN; WILLIAM C. BATON; ZHIQIANG LIU
Firms	Attn: John E. Flaherty; Carella, Byrne, Cecchi, Olstein, Brody & Agnello, P.C.; Carella, Byrne, Cecchi, Olstein, Brody & Agnello, PC; McCarter & English, LLP; McCarter and English, LLP; Office of the United States Atorney; Patterson Belknap Webb & Tyler LLP; Patunas Law LLC; Patunas Tarantino LLC; Saul Ewing Arnstein & Lehr LLP; Teva Pharmaceuticals USA, Inc.; U S Department of Justice; U.S. Department of Justice; United States Department of Justice, Civil Division, Commercial Litigation Branch
Link to Docket	External link to docket

Details for JANSSEN PRODUCTS, L.P. v. LUPIN LIMITED (D.N.J. 2010)

Date Filed	Document No.	Description	Snippet	Link To Document
2016-06-15	1073		of U.S. Patent No. 7,126,015 (the ‘015 Patent), and claim 4 of U.S. Patent No. 7,700,645 (the ‘645… the components protected by the ‘015 Patent or the ‘645 Patent. Id. Defendants Mylan and… the Patents and the end of any “associated pediatric exclusivity period” for the ‘645 Patent. Id. …would infringe claim 1 of the ‘015 Patent and/or claim 4 of the ‘645 Patent and enjoining Lupin from producing…Federal Rule of Civil Procedure 62.1. The case, a patent infringement action, is currently on appeal	External link to document
2013-01-18	270		OPENING BRIEF FOR THE DISPUTED TERM IN U.S. PATENT RE43,596 (Attachments: # 1 Declaration of Irena Royzman…2010 19 August 2014 2:10-cv-05954 830 Patent Defendant District Court, D.	External link to document
2013-01-18	271		Opening Brief of Defendants Regarding U.S. Patent No. RE43,596 E by LUPIN LIMITED, LUPIN PHARMACEUTICALS…2010 19 August 2014 2:10-cv-05954 830 Patent Defendant District Court, D.	External link to document
2013-02-19	289		Responsive Markman Brief Regarding U.S. Patent No. RE43,596 E (Attachments: # 1 Supplemental Declaration… Responsive Markman Brief Regarding U.S. Patent No. RE43,596 E, # 2 Exhibit 7 to Declaration of Joseph… Responsive Markman Brief Regarding U.S. Patent No. RE43,596 E)(PATUNAS, MICHAEL) (Entered: 02/19/2013…2010 19 August 2014 2:10-cv-05954 830 Patent Defendant District Court, D.	External link to document
2013-05-09	334		U.S. Patent No. 5,843, 946 (the “‘946 patent”) and U.S. Patent No. 7,700,645 (the “‘645 patent”). …asserted two more patents against Teva, U.S. Patent Nos. RE42,889 (the “‘889 patent”) and RE43,596 (…of the ‘946 patent, noting that claim 25 of the ‘889 patent and claim 7 of the ‘946 patent would both …on March 24, 2011, adding U.S. Patent No. 6,248,775 (the “‘775 patent”). (See D.E. 6, Civil Action…the ‘889 patent on June 13, 2012, and its complaint asserting infringement of the ‘596 patent August 24	External link to document
2013-06-18	373		U.S. Patent No. 5,843,946 (“the ‘946 patent”) and U.S. Patent No. 7,470,506 (“the ‘506 patent”). Plaintiffs…objections as to the ‘506 patent, and simply attempt to sweep them into the ’946 patent. Government Plaintiffs…its proposed amendment with respect to the ‘946 patent prior to August 7, 2012. Id. at 8-9. Instead, Janssen…for its proposed defenses to the ‘946 and ‘506 patents. Janssen Pls. Br. at 10-11. Finally, Janssen concludes…way eliminates all of Teva’s defenses to the ‘506 patent infringement claim).	External link to document